Scott J. Weir is director of the Institute for Advancing Medical Innovation (IAMI) at the University of Kansas. IAMI conducts product development-focused translational research on products with clear paths to market and assists the university and the region in advancing medical innovations technologies through product development and commercialization-focused decision points, to create and enhance product value proposition. IAMI is establishing and executing projects through high-performance collaborations with industry, academia, government and disease philanthropy organizations. Weir co-leads one of four cancer research programs within the University of Kansas Cancer Center and also serves as associate director of translational research.
Weir’s specific areas of expertise are in clinical pharmacology, pharmacokinetics, biopharmaceutics, and developing innovative approaches to lead optimization and early drug development. He has built a reputation of being innovative in bridging the "Valley of Death" through high-performance public-private partnerships as well as repurposing approved drugs and rescuing abandoned drugs.
Weir received his doctorate in pharmacokinetics and biopharmaceutics from the University of Nebraska Medical Center and his Doctor of Pharmacy from the University of Nebraska College of Pharmacy.